Association of Glucagon‐Like Peptide‐1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
Pooled result · Psychiatric disordersResult — go to the resultRelative risk 0.96 95% CI 0.85–1.08Authors' conclusion
GLP-1 RAs use was not associated with the risk of psychiatric disorders, including depression, suicide or anxiety.
Study context
- Population
- Participants of randomised clinical trials (RCTs) comparing GLP-1 RAs with placebo or other non-GLP-1 RA treatments; PubMed, EMBASE, Cochrane Library, Web of Science to June 13, 2025
- Participants
- 133,378 participants86 RCTs
- Comparison
- GLP-1 RA vs placebo or other non-GLP-1 RA treatments
- Outcome
- Incidence of psychiatric disorders (treatment-emergent adverse events)
Methodological detailsPRISMA, Cochrane risk-of-bias tool, GRADE
- PRISMA
- Cochrane risk-of-bias tool
- GRADE
Pooled result
Psychiatric disorders
Relative risk
0.96
95% CI 0.85–1.08
GLP-1 RAsvs Control
RR 0.96 (95% CI 0.85–1.08)
As reported in the abstract
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| Depression | 0.88 (0.70–1.10) | |
| Suicide | 0.90 (0.59–1.38) | |
| Anxiety | 0.92 (0.72–1.19) | |
| Sleep disorder | 0.98 (0.70–1.37) | |
| Bipolar disorder | 1.19 (0.56–2.55) | |
| Delirium | 1.11 (0.74–1.66) | |
| Addictive disorder | 0.89 (0.45–1.77) | |
| Schizophrenia | 1.45 (0.61–3.47) | |
| 0.20.5125Relative risk (log scale) |
Subgroups and meta-regression
- No significant associations by drug type, indication, dose, treatment duration, comparator type, baseline BMI, trial designation, age, baseline psychiatric disorders or reporting category
- Meta-regression: no significant effect of changes in FPG, HbA1c, weight or BMI on risk of psychiatric disorders
Original publication
Association of Glucagon‐Like Peptide‐1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Diabetes Obes Metab. Published 19 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →